Non-classic apparent mineralocorticoid excess syndrome: current evidence and future challenges
| dc.contributor.author | Carvajal, Cristian A. | |
| dc.contributor.author | Tapia-Castillo, Alejandra | |
| dc.contributor.author | Uslar, Thomas | |
| dc.contributor.author | Vaidya, Anand | |
| dc.contributor.author | Pérez, Jorge A. | |
| dc.contributor.author | Baudrand, René | |
| dc.contributor.author | Fardella, Carlos E. | |
| dc.coverage.spatial | Estados Unidos | |
| dc.date.accessioned | 2026-11-20T15:26:01Z | |
| dc.date.issued | 2026-10-30 | |
| dc.description.abstract | Hypertension affects over 1.3 billion people worldwide and is the leading modifiable cause of cardiovascular morbidity and mortality. Approximately one-third of individuals with hypertension exhibit a low-renin phenotype, a clinically heterogeneous subgroup in which the underlying etiology remains uncharacterized in most cases. Among its mechanistic contributors, non-classic apparent mineralocorticoid excess (NC-AME) represents a prevalent and under recognized cause of cortisol-mediated mineralocorticoid receptor over activation that has, to date, lacked a formal clinical definition, standardized diagnostic criteria, or evidence-based therapeutic framework. This review addresses that gap. NC-AME is formally defined as a syndrome of partial 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) insufficiency occurring in the absence of biallelic human HSD11B2 variants, biochemically characterized by an elevated cortisol-to-cortisone (F/E) ratio and low cortisone concentration, and typically associated with low plasma renin, normal-to-low aldosterone, and elevated blood pressure. The review consolidates evidence across 3 mechanistic domains, genetic and epigenetic dysregulation of HSD11B2 gene, endogenous and exogenous enzyme inhibition, and patient-specific alterations (ie, age, sex, renal function), and proposes a structured LC-MS/MS-based diagnostic algorithm, and a resource-adapted diagnostic approach. Mineralocorticoid receptor antagonists are endorsed as mechanism-directed first-line therapy, with blood pressure and renin normalization as co-primary treatment targets. Acquired and reversible causes are classified separately to guide clinical management. A research agenda is advanced to drive threshold standardization, multicenter validation, and integration of NC-AME into hypertension guidelines across endocrinology, cardiology, and nephrology. | |
| dc.identifier.citation | Endocrine Reviews, Vol. 00, N° 0 (2026) p. 1-16 | |
| dc.identifier.doi | https://doi.org/10.1210/endrev/bnag040 | |
| dc.identifier.issn | 1945-7189 | |
| dc.identifier.orcid | https://orcid.org/0000-0002-0668-412X | |
| dc.identifier.orcid | https://orcid.org/0000-0002-6081-1468 | |
| dc.identifier.orcid | https://orcid.org/0000-0001-7213-855X | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12254/7861 | |
| dc.language.iso | en | |
| dc.publisher | Oxford University Press | |
| dc.relation.ispartof | Endocrine reviews | |
| dc.rights | Atribución-NoComercial-CompartirIgual 3.0 Chile (CC BY-NC-SA 3.0 CL) | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/3.0/cl/ | |
| dc.subject | Low renin hypertension | |
| dc.subject | Apparent mineralocorticoid excess | |
| dc.subject | 11β-hydroxysteroid dehydrogenase type 2 | |
| dc.subject | Mineralocorticoid receptor | |
| dc.subject | Non-classic AME | |
| dc.subject | Cortisol metabolism | |
| dc.title | Non-classic apparent mineralocorticoid excess syndrome: current evidence and future challenges | |
| dc.type | Artículo | |
| oaire.citation.endPage | 16 | |
| oaire.citation.issue | 00 | |
| oaire.citation.startPage | 1 | |
| oaire.citation.volume | 00 |
Archivos
Bloque original
1 - 1 de 1
Cargando...
- Nombre:
- 2026_Non-classic apparent mineralocorticoid excess syndrome- current evidence and future challenges.pdf
- Tamaño:
- 841,36 KB
- Formato:
- Adobe Portable Document Format
